Baker & Hostetler LLP
10/05/2026 | Press release | Distributed by Public on 10/05/2026 11:38
BakerHostetler Advises Summit Therapeutics in $2B Equity Investment by AstraZeneca
10/05/2026|1 minute read
Share
Partner Adam Finerman led a team that included Associates Alexander Davis and Sean Cheatle as they provided legal counsel to Summit Therapeutics Inc. in an agreement whereby AstraZenecamade a $2.0 billion equity investment in Summit through the purchase of convertible preferred shares.
In addition to receiving the equity investment, Summit entered into a clinical collaboration agreement with AstraZeneca to evaluate sonesitatug vedotin (Sone-ve) in combination with ivonescimab with the intent to start studies in certain gastrointestinal (GI) cancer settings imminently. Sone-ve is a potential global first-in-class Claudin 18.2-targeting ADC with several ongoing trials underway in GI cancers. Ivonescimab is a novel, potential first-in-class investigational PD-1 / VEGF bispecific antibody.
The transaction closed on Oct. 5, 2026.
Related Services
Plus
Baker & Hostetler LLP published this content on October 05, 2026, and is solely responsible for the information contained herein. Distributed via Public Technologies (PUBT), unedited and unaltered, on October 05, 2026 at 17:38 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]